Tarec Film-Coated Tablet 80 mg (Valsartan)
Valsartan
Prescription medication
Korea Sandos Co., Ltd.
MFDS item code 200511378 · Notified 2005.10.24
This product's status changed to Approval withdrawn on 2023.06.26. It may no longer be sold, so consult a doctor or pharmacist before taking it.
Treatment of essential hypertension, improvement of heart failure, reduction of the risk of death after myocardial infarction
This medication effectively lowers blood pressure in patients with essential hypertension and can also be used in heart failure patients who are intolerant to ACE inhibitors. Additionally, it helps reduce the mortality risk in stable patients with left ventricular dysfunction or contractile dysfunction after myocardial infarction. In other words, this medication is very useful for managing hypertension, treating certain heart failure patients, and reducing the risk of death after myocardial infarction.
Essential hypertension Take with water during a meal or between meals. If possible, it is recommended to take this medicine at the same time each day (e.g., in the morning). Adults: The recommended oral dose is 80 mg of valsartan once daily, regardless of sex or race. The blood pressure-lowering effect develops gradually within 2 weeks and reaches its maximum after 4 weeks. For patients whose blood pressure is not adequately controlled, the dose may be increased to 160 mg daily or a diuretic may be co-administered. If further blood pressure reduction is required, the dose may be increased up to a maximum of 320 mg daily. Elderly patients (75 years and older): Initiate treatment with 40 mg of this medicine once daily. Patients with renal impairment: Creatinine clearance 20 ∼ 50 mL/min: No dose adjustment is necessary. Creatinine clearance 10 ∼ 20 mL/min: Initiate treatment with 40 mg of this medicine once daily. Creatinine clearance less than 10 mL/min and patients on dialysis: Do not administer this medicine. Patients with volume depletion: In patients with volume depletion (e.g., patients taking high doses of diuretics whose dose cannot be reduced), initiate treatment with 40 mg of this medicine once daily. Patients with hepatic impairment: In patients with mild or moderate hepatic impairment, initiate treatment with 40 mg of this medicine once daily, and do not exceed 80 mg daily. Do not administer this medicine to patients with severe hepatic impairment, cirrhosis, or cholestasis. Heart failure Adults: The recommended initial oral dose is 40 mg of this medicine twice daily. The dose may be increased to 80 mg or 160 mg per dose. When co-administering a diuretic, consider reducing the diuretic dose. The maximum daily dose is 320 mg, given in divided doses. Triple combination therapy with this medicine, an ACE inhibitor, and a beta-blocker is not recommended. Reduction of the risk of death after myocardial infarction Adults: Treatment may be initiated within 12 hours after the onset of myocardial infarction. The recommended initial dose is 20 mg of this medicine twice daily; over the following several weeks, increase the dose according to the patient's tolerability to 40 mg, 80 mg, and 160 mg per dose twice daily. Consider reducing the dose if symptoms of hypotension or renal failure occur. This medicine may also be given to patients receiving other treatments after myocardial infarction (e.g., thrombolytic agents, acetylsalicylic acid, beta-blockers, and statins). However, co-administration with an ACE inhibitor is not recommended. Patients with renal impairment: No dose adjustment is necessary if creatinine clearance is 10 mL/min or higher. However, because there is no experience with use in patients with creatinine clearance less than 10 mL/min or in patients on dialysis, do not administer this medicine. Patients with hepatic impairment: In patients with mild or moderate hepatic impairment, it is preferable not to exceed 80 mg of this medicine per day. If administering more than 80 mg per day, consider whether the benefits of treatment outweigh the risks when increasing the dose. Do not administer this medicine to patients with severe hepatic impairment, cirrhosis, or cholestasis.
Essential hypertension: Safety and efficacy have not been established in children and adolescents under 18 years of age. Safety and efficacy have not been established in children and adolescents under 18 years of age.
This medication can cause serious harm to the fetus if taken during pregnancy, especially in the second and third trimesters, so it must be discontinued immediately upon confirmation of pregnancy. Women who are pregnant or may become pregnant, patients with severe liver or kidney disease, and patients with certain hereditary angioedema should not take this medication. Elderly patients, patients with hyperkalemia, liver disease, and heart failure should take this medication with caution, as it may cause a sudden drop in blood pressure; starting with a low dose and observing their condition carefully is recommended. During treatment with this medication, side effects such as headache, dizziness, cough, diarrhea, and fatigue may occur; in severe cases, it may lead to hypotension, renal impairment, and hyperkalemia, necessitating periodic testing. Patients undergoing dialysis or on strict sodium restriction, as well as patients on diuretics, are at higher risk of hypotension and should exercise caution when taking this medication. This medication may interact with other antihypertensives, potassium-sparing diuretics, and certain non-steroidal anti-inflammatory drugs, so it is essential to consult a physician or pharmacist. Breastfeeding women should avoid taking this medication; if it is necessary, breastfeeding should be discontinued. The safety and efficacy for children and adolescents under 18 have not been established and it is advisable not to use it. In cases of overdose, there may be a rapid drop in blood pressure and loss of consciousness, requiring immediate medical attention. This medication should be kept out of reach of children and transferring it to other containers should be avoided as it can affect its quality.
Not everyone experiences these, and they can vary from person to person.
This medication is sensitive to air and moisture and should be stored in a sealed container. It is also important to keep it in a cool place below 30 degrees Celsius to maintain its efficacy.
Light reddish round film-coated tablet
98 tablets (14 tablets/PTP packaging x 7)
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Valsartan
Prescription medication
Korea Sandos Co., Ltd.

Valsartan 80mg
Tablet · Prescription medication
Novartis Korea Co., Ltd.

Valsartan 160mg
Tablet · Prescription medication
Novartis Korea Co., Ltd.

Valsartan 40mg
Tablet · Prescription medication
Samsung Novartis Co., Ltd.
Valsartan
Prescription medication
Korea Sandos Co., Ltd.

Valsartan
Prescription medication
Korea Sandos Co., Ltd.

Valsartan 320mg
Tablet · Prescription medication
Novartis Korea Co., Ltd.

Valsartan 80mg
Tablet · Prescription medication
Dongkwang Pharmaceutical Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.